Phaseline

Companies › Signet Therapeutics

Signet Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SIGX1094R–Phase 1Advanced Solid TumorsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06739291SIGX1094RPhase 1Advanced Solid TumorsOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.